Current evidence shows some potential for the use of collagen hydrolysate as an option for management of patients with OA. However there is still room for progress in terms of laboratory and clinical research before any definitive conclusion can be made. Harmonization of outcomes in preclinical studies and longer randomized placebo-controlled trials in larger populations with the use of recommended and validated endpoints are warranted before collagen derivatives can be recommended by large scientific societies.
Vicenza
Sede Amministrativa e legale
via E. Fermi, 49
36057 Arcugnano, Vicenza (VI) - Italia
Tel. +39 0444 289366
Fax: +39 0444 285272
Torino
Centro Polifunzionale di produzione
Via G. Agnelli, 3
10020 Riva presso Chieri, Torino (TO) - Italia
Copyright © 2023 Bioteck S.p.A. - Privacy Policy - Cookie Policy